Search PubMed⌕ Search

Biomedical subjects

R Bataille

Publications and source records attributed to R Bataille.

At least 271 records · Page 15Linked to original sources

Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression.

In this study, we have evaluated the proliferation and the phenotype of human plasma cells of different origins, i.e., from tonsil, peripheral blood, bone marrow as well as plasma cells generated in vitro from memory B cells. We have demonstrated that plasma cells from tonsil, peripheral blood, as well as those generated in vitro, were highly proliferating and presented a homogeneous CD45bright phenotype. In contrast, bone marrow plasma cells were heterogeneous for CD45 expression but their proliferation was restricted to the CD45bright compartment. Subsequently, their CD45 expression decreased with proliferation arrest and final maturation. We also studied the proliferation of abnormal plasma cells, i.e., peripheral blood reactive plasmacytoses and multiple myeloma (MM). All reactive plasmacytoses turned out to be homogeneous expansions of CD45bright plasma cells with unusually high labeling index. In contrast, CD45 expression was heterogeneous in MM as in normal bone marrow. However, a minor CD45bright population was also always the most proliferating one as opposed to a major population of less or non-proliferating myeloma cells characterized by a weaker or a lack of CD45 expression. In conclusion, proliferation is linked to plasma-cell generation and a CD45bright phenotype is the hallmark of the most proliferating normal, reactive as well as malignant plasma cells.

B-Lymphocytes↗

Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.

When bone-marrow cells from patients with multiple myeloma (MM) were seeded in short-term cultures, a spontaneous proliferation of the myeloma cells occurred for most of the patients with active disease and proliferating myeloma cells in vivo. In all cases, this spontaneous proliferation was inhibited by anti-IL-6 monoclonal antibodies (mabs). Moreover, myeloma cell lines, completely dependent upon exogenous IL-6 for their growth, could be reproducibly established by initially stimulating the myeloma cells with both IL-6 and GM-CSF. These results demonstrate that IL-6 is a major paracrine myeloma-cell growth factor in vitro. High serum IL-6 levels were observed in MM patients with active disease, especially patients with terminal disease. High IL-6 mRNA levels were found in bone-marrow cells of MM patients, mainly in myeloid and monocytic cells, in vivo. The myeloma cells did not express IL-6 mRNA. Injection of anti-IL-6 mabs to MM patients with terminal disease and extramedullary proliferation, completely blocked the myeloma-cell proliferation in vivo and completely inhibited the serum IL-6 bioactivity and the serum CRP levels. One patient with plasma cell leukemia and hypercalcemia was treated for two months with anti-IL-6 mabs and maintain in remission for 2 months without major side effects. Interestingly, the serum calcium levels also decreased in these patients. All these results show that IL-6 is the main cytokine responsible not only for the myeloma-cell proliferation in vivo, but presumably also for the large bone resorption processes observed in human MM.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

CD5 positive B lymphocytes: a link between autoimmunity and B-cell oncogenesis.

A strong relationship exists between autoimmunity and B-cell oncogenesis. Recent evidence indicates that CD5-positive B-cells are involved in both the production of (germ-line encoded) autoantibodies and the clonal B-cell expansions. Thus, this special B-cell subset represents a strong link between autoimmune state and B-cell malignancies. Immunotherapy of both autoimmune diseases and B-cell malignancies. Immunotherapy of both autoimmune diseases and B-cell cancers should consider the relationship between both processes.

Animals↗

Immunofixation improves the detection of monoclonal gammopathy of undetermined significance (M.G.U.S.) in patients with rheumatoid arthritis.

Monoclonal gammopathy of undetermined significance (MGUS) was detected by immunofixation (IFX) in 6% of patients with rheumatoid arthritis (RA), whereas it was detected by immunoelectrophoresis in only 1% of these patients. Most of the patients with both RA and MGUS had polyclonal B cell activation, together with their monoclonal band, extra-articular features and long-lasting disease, which suggests a direct relationship between MGUS and RA status.

Arthritis, Rheumatoid↗

Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma.

Measuring serum beta-2-microglobulin (B2M) in 90 patients with multiple myeloma (MM) from diagnosis to death (83 cases), or to the terminal phase of their disease (7 cases), we have obtained evidence that 9% of them retained normal serum B2M levels during the whole of their follow-up. This was observed in 6 IgA MM, in one light chain MM only and in one non-secretory MM. These data suggest a lack of B2M production and/or secretion by some myeloma tumors. This could limit the use of B2M as clinical marker in MM.

Humans↗